The heparin-protamine interaction. A review

Journal of Cardiovascular Surgery

Volumn 40, Issue 5, 1999, Pages 659-666

  Carr, J A ^a   Silverman, N ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Anticoagulants; Cardiopulmonary bypass; Heparin; Protamines

Indexed keywords

COMPLEMENT; HEPARIN; HISTAMINE; NITRIC OXIDE; PROTAMINE; THROMBOXANE;

ARTICLE; CARDIOPULMONARY BYPASS; CARDIOVASCULAR EFFECT; DIASTOLIC BLOOD PRESSURE; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART RATE VARIABILITY; HUMAN; HYPOTENSION; LUNG ARTERY PRESSURE; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ANTICOAGULANTS; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; DRUG INTERACTIONS; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; PROTAMINES; VASCULAR RESISTANCE;

EID: 0032704702     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. United States Bureau of the Census. Statistical Abstract of the United States: 1997 (117th edition) Washington, DC, 1997.
2. Stanker LH, Wyrobek A, McKeown C, Balhorn R. Identification of the binding site of two monoclonal antibodies to human protamine. Molecular Immunol 1993;30:1633-8.
3. Alban S, Harenberg J. Neutralization of heparins and heparin-related oligosaccharides by protamine and polybrene. Pharmacol Lett 1991;1:37-40.
4. Piazolo L, Harenberg J, Malsch R, Heene DL. Binding of flourescent-labeled low molecular mass heparin to latex microspheres and to rat and human leukocytes. Semin Thromb Hemost 1994;20:227-35.
5. Goldman B, Joison J, Austen W. Cardiovascular effects of protamine sulfate. Ann Thorac Surg 1969;7:459-63.
6. Fadali M, Ledbetter M, Papacostas C, Duke L, Lemole G. Mechanism responsible for the cardiovascular depressant effect of protamine sulfate. Ann Surg 1974;180:232-7.
7. Hulin MS, Wakefield TW, Andrews PC, Wrobleski SK, Kadell AM, Downing LJ et al. Comparison of the hemodynamic and hematologic toxicity of a protamine variant after reversal of low-molecular-weight heparin anticoagulation in a canine model. Lab Animal Sci 1997;47:153-60.
8. Rogers K, Milne B, Salerno TA. The hemodynamic effects of intra-aortic versus intravenous administration of protamine for reversal of heparin in pigs. J Thorac Cardiovasc Surg 1983;85: 851-5.
9. Wakefield TW, Hantler CB, Wrobleski SK, Crider B, Stanley JC. Effects of differing rates of protamine reversal of heparin anticoagulation. Surgery 1996;119:123-8.
10. Horrow JC. Protamine: a review of its toxicity. Anesth Analg 1985;64:348-61.
11. Oe M, Asou T, Morita S, Yasui H, Kouichi T. Protamine-induced hypotension in heart operations: application of the concept of ventricular-arterial coupling. J Thorac Cardiovasc Surg 1996;112: 462-71.
12. Katz NM, Kim YD, Siegelman R, Ved SA, Ahmed SW, Wallace RB. Hemodynamics of protamine administration: comparison of right atrial, left a trial, and aortic injections. J Thorac Cardiovasc Surg 1987;94:881-6.
13. Hird RB, Wakefield TW, Mukherjee R, Jones BU, Crawford FA, Andrews PC et al. Direct effects of protamine sulfate on myocyte contractile processes: cellular and molecular mechanisms. Circulation 1995;92:433-45.
14. O SJ, Cox MH, Mukherjee R, Clair MJ, Crawford FA, Spinale FG. Direct and interactive effects of cardioplegic arrest and protamine on myocyte contractility. Ann Thorac Surg 1996;62:489-93.
15. Cox MH, O SJ, Clair MJ, Mukherjee R, Wakefiled TW, Andrews PC et al. Differential effects of novel protamine variants on myocyte contractile function with left ventricular failure. Surgery 1997;121:304-13.
16. Chenoweth DE, Cooper SW, Hugli T, Stewart R, Blackstone E, Kirklin J. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a analphylatoxins. N Engl J Med 1981;304:497-503.
17. Cavarocchi NC, Schaff HV, Orszulak T, Homburger H, Schnell W, Pluth J. Evidence for complement activation by protamine-heparin interaction after cardiopulmonary bypass. Surgery 1985;98: 525-31.
18. Shastri KA, Logue GL, Stern M, Rehman S, Raza S. Complement activation by heparin-protamine complexes during cardiopulmonary bypass: effect of C4a null allele. J Thorac Cardiovasc Surg 1997;114:482-8.
19. Weiler J, Packard B. Methylprednisolone inhibits the alternative and amplification pathways of complement. Infect Immun 1982;40:1011-6.
20. Loubser PG. Effect of methylprednisolone on complement activation during heparin neutralization. J Cardiovasc Pharm 1997;29:23-7.
21. Habazetti H, Martinek V, Vollmar B, Conzen P. Enhancement of the leukocyte-endothelial cell interaction in connecting venules of skeletal muscle by protamine. J Thorac Cardiovasc Surg 1997;113:784-91.
22. Grupe R, Ziska T. Inhibition of histamine secretion from mast cells by lipoxygenase and cyclooxygenase inhibitors. Agents Actions 1994;41:C34-6.
23. Patella V, Ciccarelli A, Lamparter-Schummert B, DePaulis A, Adt M, Marone G. Heterogeneous effects of protamine on human mast cells and basophils. Br J Anesth 1997;78:724-30.
24. Kanbak M, Kahraman S, Celebioglu B, Akpolat N, Ercan S, Erdem K. Prophylactic administration of histamine 1 and/or histamine 2 receptor blockers in the prevention of heparin-and protamine-related hemodynamic effects. Anesth Intensive Care 1996;24:559-63.
25. Baraka A, Choueir P. Hydrocortisone pretreatment for attenuation of protamine-induced adverse hemodynamic reactions. J Cardiothorac Vase Anesth 1995;9:481-2.
26. Friedman M, Johnson R, Wang S, Dai H, Thurer R, Weintraub R et al. Pulmonary microvascular responses to protamine and histamine. J Thorac Cardiovasc Surg 1994;108:1092-7.
27. Sugi K, Esato K. Effect of a thromboxane synthetase inhibitor on protamine-induced circulatory changes in sheep. Surgery 1992;114:586-90.
28. Morel DR, Lowenstein E, Nguyenduy T, Robinson D, Repine J, Chenoweth DE et al. Acute pulmonary vasoconstriction and thromboxane release during protamine reversal of heparin anticoagulation in awake sheep: evidence for the role of reactive oxygen metabolites following nonimmunological complement activation. Cire Res 1988;62:905-15.
29. Mendeloff EN, Liang IY, Swain JA, Clark RE. Thromboxane A2 receptor-specific antagonism in hypothermic cardiopulmonary bypass. Ann Thorac Surg 1994;57:999-1006.
30. 111In-protamine. J Appl Physiol 1993;75:963-71.
31. Vollmar B, Conzen PF, Habazettl H, Yekebas E, Peter K. Heparin-protamine reactions in pigs: role of oxygen free radicals. J Appl Physiol 1993;74:2412-9.
32. 2 activity and prostacyclin synthesis in patients undergoing cardiac surgery. J Clin Invest 1995;95:1062-9.
33. Aissa J, Nathan N, Arnoux B, Benveniste J. Biochemical and cellular effects of heparin-protamine injection in rabbits are partially inhibited by a PAF-acether receptor antagonist. Eur J Pharmcol 1996;302:123-8.
34. Li JM, Hajarizadeh H, LaRosa C, Rohrer M, VanderSalm T, Cutler B. Heparin and protamine stimulates the production of nitric oxide. J Cardiovasc Surg 1996;37:445-52.
35. Upchurch GR, Welch GN, Freedman J, Fabian A, Pigazzi A, Scribner A et al. High-dose heparin decreases nitric oxide production by cultured bovine endothelial cells. Circulation 1997;95:2115-21.
36. Raikar GV, Hisamochi K, Raikar BN, Schaff HV. Cardiopulmonary bypass, myocardial management, and support techniques: nitric oxide inhibition attenuates systematic hypotension produced by protamine. J Thorac Cardiovasc Surg 1996;111:1240-6.
37. Castresana MR, Zhang LM, Newman WH. Protamine does not affect the formation of cGMP or cAMP in pig vascular smooth muscle cells in response to vasodilators. Crit Care Med 1995;23: 939-43.
38. Hakim T, Picone A, Oleary C, Camporesi E. Protamine-induced pulmonary venoconstriction in heparinized pigs. Anesth Analg 1995;81:38-41.
39. Evora P, Pearson P, Schaff HV. Protamine induces endothelium-dependent vasodilation of the pulmonary artery. Ann Thorac Surg 1995;60:405-9.
40. Takenoshita M, Sugiyama M, Okuno Y, Inagaki Y, Yoshiya I, Shimazaki Y. Anaphylactoid reaction to protamine confirmed by plasma tryptase in a diabetic patient during open heart surgery. Anesthesiology 1996;84:233-5.
41. Abe K, Miyamoto Y, Ohnishi K. Hyperthermia after cardiac surgery. Can J Anesth 1997;44:662-5.
42. Belboul A, al-Khaja N. The effect of protamine on the epicarcial microflow and the graft flow in open-heart surgery. Perfusion 1997;12:99-106.
43. Umbrain V, Christiaens F, Camu F. Intraoperative coronary thrombosis: can aprotinin and protamine be incriminated? J Cardiothorac Vasc Anesth 1994;8:198-201.
44. Levy JH. Antibody formation after drug administration after cardiac surgery: parameters for aprotinin use. J Heart Lung Transplant 1993;12:S26-33.
45. Levy JH, Zaidan JR, Faraj B. Prospective evaluation of risk of protamine reactions in patients with NPH insulin dependent diabetes. Anesth Analg 1986;65:739-42.
46. Levy JH, Schwieger IM, Zaidan J. Evaluation of patients at risk for protamine reactions. J Thorac Cardiovasc Surg 1989;98:200-4.
47. Weiss ME, Nyhan D, Peng Z, Horrow J, Lowenstein E, Hirshman C et al. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med 1989;320:886-92.
48. Dykewicz MS, Kim HW, Orfan N, Yoo T, Lieberman P. Immunologic analysis of anaphylaxis to protamine component in neutral protamine Hagedorn human insulin. J Allergy Clin Immun 1994;93:117-25.
49. Nyhan DP, Shampiane EL, Hirshman C, Hamilton R, Frank S, Baumgartner W et al. Single doses of intravenous protamine result in the formation of protamine-specific IgE and IgG antibodies. J Allergy Clin Immun 1996;97:991-7.
50. Horrow JC, Pharo GH, Levit L, Freeland C. Neither skin test nor serum enzyme-linked immunosorbent assay tests provides specificity for protamine allergy. Anesth Analg 1996;82:386-9.
51. Stanker LH, Wyrobek A, McKeown C, Balhorn R. Identification of the binding site of two monoclonal antibodies to human protamine. Molec Immun 1993;30:1633-8.
52. Dehmer GJ, Fisher M, Tate D, Teo S, Bonnem E. Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans. Circulation 1995;91:2188-94.
53. Bernabei A, Gikakis N, Maione T, Kowalska M, Yan Z, Niewiarowski S et al. Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1995;109: 765-71.
54. Cook J, Niewiarowski S, Yan Z, Schaffer L, Lu W, Stewart G et al. Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes. Circulation 1992;85:1102-7.
55. Clark-Lewis I, Dewald B, Geiser T, Moser B, Baggiolini M. Platelet factor 4 binds to interleukin 8 receptors and activates neutrophiles when its N-terminus is modified with Glu-Leu-Arg. Proc Natl Acad Sci USA 1993;90:3574-9.
56. Kurrek M, Winkler M, Robinson D, Zapol W. Platelet factor 4 injection produces acute pulmonary hypertension in the awake lamb. Anesthesiology 1995;82:183-8.
57. Michelsen LG, Mutsuhito K. Heparinase 1 (neutralase) reversal of systemic anticoagulation. Anesthesiology 1996;85:339-46.
58. Ammar T, Fisher CF. The effects of heparinase 1 and protamine on platelet reactivity. Anesthesiology 1997;86:1382-6.